Episode
2411: Poolbeg Pharma: What US Payers Really Said
- Podcast
- The Vox Markets Podcast
- Published
- Jun 3, 2026
- Duration seconds
- 881
- Processing state
not_requested- Canonical source
- https://audioboom.com/posts/8911222
Actions
POST https://stenobird.com/v1/public/podcasts/the-vox-markets-podcast-3914537/episodes/2411-poolbeg-pharma-what-us-payers-really-said/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-vox-markets-podcast-3914537/2411-poolbeg-pharma-what-us-payers-really-said.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Watch on YouTube Independent US payer research commissioned by Poolbeg Pharma shows strong commercial backing for POLB 001 — a first-in-class preventative for cancer immunotherapy-induced CRS. Chris from Acumentis Global on what payers said, and what it means for the commercial opportunity ahead.